Healthcare

Brand-name drug companies could put off introducing new medicine in Canada and scale back research here if the country makes a major shift to cheaper generic alternatives under a national pharmacare plan, according to an internal federal analysis.

At our walk-in clinic recently, I saw a 60-year-old male with a most curious rash on his right cheek (see picture). Historically (I usually acquire a great deal of help from history), the rash was complex. It had actually healed spontaneously a couple of times.